Sign up to save your podcasts
Or
Share Eline Giraud and Elise Smolders on QT interval prolongation potential of anticancer
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Eline Giraud and Elise Smolders on QT interval prolongation potential of anticancer
Eline Giraud and Elise Smolders from the (Radboud University Medical Center, Nijmegen, Netherlands) discuss their Review on QT interval prolongation potential of anticancer and supportive drugs.
Read the full Review:
The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
View all episodes
By The Lancet Group
5
11 ratings
Eline Giraud and Elise Smolders from the (Radboud University Medical Center, Nijmegen, Netherlands) discuss their Review on QT interval prolongation potential of anticancer and supportive drugs.
Read the full Review:
The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
More shows like The Lancet Oncology in conversation with
View all
Nature Podcast
764 Listeners
Science Magazine Podcast
812 Listeners
JAMA Editors' Summary
129 Listeners
TED Talks Daily
11,418 Listeners
NEJM Interviews
123 Listeners
6 Minute English
1,825 Listeners
NEJM This Week
313 Listeners
Journal of Clinical Oncology (JCO) Podcast
40 Listeners
Practical Neurology Podcast
35 Listeners
JAMA Clinical Reviews
488 Listeners
ASCO Daily News
55 Listeners
ASCO Guidelines
46 Listeners
The Readout Loud
314 Listeners
The Uromigos
59 Listeners
The Lancet Voice
22 Listeners
The Lancet Child & Adolescent Health in conversation with
0 Listeners
The Lancet Digital Health in conversation with
0 Listeners
The Lancet Global Health in conversation with
2 Listeners
The Lancet Psychiatry in conversation with
0 Listeners
The Lancet Respiratory Medicine in conversation with
1 Listeners
The Lancet in conversation with
0 Listeners
The Lancet Haematology in conversation with
0 Listeners
The Lancet Gastroenterology & Hepatology in conversation with
0 Listeners
The Lancet Diabetes & Endocrinology in conversation with
2 Listeners
The Lancet Infectious Diseases in conversation with
0 Listeners
The Lancet Healthy Longevity in conversation with
0 Listeners
The Lancet Public Health in conversation with
2 Listeners
The Lancet Microbe in conversation with
0 Listeners
In conversation with...
0 Listeners
eBioMedicine in conversation with
0 Listeners
eClinicalMedicine in conversation with
0 Listeners
The Lancet Rheumatology in conversation with
0 Listeners
Two Onc Docs
164 Listeners
The Lancet Regional Health in conversation with
0 Listeners